L-Glutamine

线粒体动力学：三阴性乳腺癌个性化管理的一个有前景的工具 关键信息 关键信息 关键信息： 1. 核心问题：三阴性乳腺癌占乳腺癌病例的15%-20%，因缺乏靶点，依赖化疗，但易产生耐药，预后差。 2. 线粒体动力学失衡：分裂蛋白(如DRP1、MFF)上调，融合蛋白(如MFN1/2、OPA1)下调，导致线粒体碎片化，促进肿瘤生长、转移和干性。 3. 代谢重编程： a) 糖酵解增强：HK2、PFK1、PKM2等酶过表达，驱动瓦博格效应，支持生物合成和耐药。 b) 谷氨酰胺成瘾：SLC1A5和GLS表达升高，为TCA循环回补和抗氧化(GSH)提供支持。 c) 脂肪酸氧化增强：CPT1A等上调，为化疗耐药细胞提供能量并抵抗凋亡。 d) 氧化应激与凋亡抵抗：活性氧水平升高，但抗氧化系统(NRF2/GSH)也上调；抗凋亡蛋白(Bcl-2、Bcl-xL、Mcl-1)和IAPs(XIAP、cIAP1/2)过表达，导致凋亡逃逸。 e) 靶向治疗策略(临床前/临床)： f) 动力学调节剂：Mdivi-1、Dynasore等抑制分裂，促进融合。 g) 代谢抑制剂：2DG、3BP(糖酵解)；CB-839、V-9302(谷氨酰胺)；Etomoxir(脂肪酸氧化)。 h) 抗氧化/凋亡调节剂：Brusatol(抑制NRF2)；BH3 mimetics(如ABT-737、Venetoclax)和IAP拮抗剂(如SM-406)。 4. 关键挑战：三阴性乳腺癌异质性、靶向治疗的正常组织毒性。 5. 未来方向：开发生物标志物指导个性化治疗，利用纳米技术提高靶向性，探索与免疫治疗的联合策略。 三阴性乳腺癌是一种侵袭性极强且具有高度转移性的乳腺癌亚型，因其缺乏雌激素受体、孕激素受体和人表皮生长因子受体2的表达，导致缺乏有效的靶向治疗手段，患者预后普遍较差。化疗是目前主要的治疗策略，但频繁出现的化疗耐药性常导致肿瘤复发和不良临床结局。近年来，越来越多的研究表明，线粒体功能障碍是三阴性乳腺癌发生发展及化疗耐药的关键因素之一，而线粒体动力学和能量代谢的紊乱在此过程中扮演着核心角色。线粒体作为细胞的能量中枢，通过氧化磷酸化生成大部分三磷酸腺苷，并深度参与细胞存活、凋亡、钙稳态和氧化还原平衡的调控。在三阴性乳腺癌中，线粒体动力学的失衡，即线粒体分裂与融合的失调，导致线粒体形态和功能异常，进而引发氧化磷酸化受损、活性氧生成增加及细胞凋亡抵抗，这些异常共同驱动了肿瘤的侵袭性和治疗抵抗。同时，三阴性乳腺癌细胞表现出显著的代谢重编程特征，包括对有氧糖酵解和谷氨酰胺的依赖性增强，以满足其快速增殖的生物合成需求并抵御细胞死亡信号。因此，深入理解线粒体功能紊乱的分子机制，并针对这些线粒体脆弱性开发新的治疗策略，为三阴性乳腺癌的个性化管理带来了新的希望。 线粒体动力学是描述线粒体通过不断融合与分裂来维持其形态和功能完整性的动态过程，这对于细胞适应内外环境压力至关重要。这一过程由一组动力蛋白相关GTP酶精密调控。线粒体分裂主要由发动蛋白相关蛋白1介导，该蛋白在细胞质中合成，并被线粒体分裂因子、线粒体动态蛋白49和51等接头蛋白招募至内质网与线粒体的接触位点，随后寡聚化形成收缩环，最终导致线粒体膜的缢缩和分裂。相反，线粒体融合则由位于外膜的丝裂融合素1和丝裂融合素2以及位于内膜的视神经萎缩蛋白1共同介导。正常情况下，分裂与融合的平衡确保了线粒体网络的稳态，并能根据细胞能量需求和应激状态进行适应性调整。然而，在三阴性乳腺癌中，这种精密的平衡被严重打破。研究发现，与正常乳腺组织及其他乳腺癌亚型相比，三阴性乳腺癌中促进分裂的蛋白显著上调，而促进融合的蛋白则往往表达下调。具体而言，的高表达与患者更差的生存率相关，其通过激活Ras/Raf/MEK/ERK信号通路促进肿瘤生长和转移。同样，作为的适配器蛋白，在线粒体分裂、干细胞特性维持和化疗耐药中发挥重要作用，其机制涉及Notch信号通路的激活。其他适配器蛋白如和也参与调控线粒体结构和生物能量学。这些过度的分裂事件导致线粒体碎片化，膜电位下降，呼吸功能减弱，代谢向糖酵解方向偏移，并伴随活性氧产生增加。与此相对，融合蛋白如和在三阴性乳腺癌中表达显著降低，其抑癌功能减弱。恢复表达可促进氧化磷酸化、抑制糖酵解，从而抑制细胞增殖并诱导凋亡；而恢复视神经萎缩蛋白1表达则能抑制上皮间质转化和基质金属蛋白酶活性，从而降低细胞的迁移和侵袭能力，并增加对化疗的敏感性。此外，非编码RNA、癌基因和抑癌基因构成的复杂调控网络也深度参与线粒体动力学的失调。例如，微小RNA可通过靶向影响线粒体动力学，而癌基因如和磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路的激活则能刺激线粒体分裂。反之，抑癌基因如p53则通过上调融合蛋白来维持线粒体完整性。这些发现共同揭示了线粒体动力学失衡是三阴性乳腺癌进展和化疗耐药的核心环节之一，靶向这一过程有望成为有效的治疗策略。 除动力学紊乱外，三阴性乳腺癌的能量代谢也发生了深刻的适应性改变，以满足其持续增殖和存活的需求。其中，最显著的特征是瓦博格效应，即即使在氧气充足的条件下，肿瘤细胞也优先选择糖酵解而非氧化磷酸化来产生能量。这种代谢转换虽然产能效率较低，但能快速提供生物合成所需的前体物质，并帮助细胞抵抗凋亡。在三阴性乳腺癌中，糖酵解途径的关键酶，如己糖激酶2、磷酸果糖激酶1和丙酮酸激酶M2的表达水平均显著高于正常组织和其他亚型，且与患者的不良预后密切相关。己糖激酶2介导的糖酵解可通过激活核因子κB通路促进肿瘤生长和转移；磷酸果糖激酶1则通过腺苷酸活化蛋白激酶/哺乳动物雷帕霉素靶蛋白信号轴驱动肿瘤干细胞特性和化疗耐药；而丙酮酸激酶M2不仅能催化糖酵解最后一步，还能在细胞核内作为转录共激活因子调控其他糖酵解酶和细胞周期基因的表达。此外，乳酸脱氢酶A和单羧酸转运蛋白4在三阴性乳腺癌中也高表达，促进了乳酸的生成和向细胞外转运，导致肿瘤微环境酸化，进而支持肿瘤的转移、血管生成和免疫抑制。靶向糖酵解途径及其上游调控因子，如缺氧诱导因子1α和磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷玛帕霉素靶蛋白通路，在临床前研究中已显示出抑制肿瘤生长的效果。除了葡萄糖，谷氨酰胺是三阴性乳腺癌另一个不可或缺的能源和碳氮来源，这种依赖性被称为“谷氨酰胺成瘾”。谷氨酰胺通过溶质载体家族1成员5转运体进入细胞后，在谷氨酰胺酶的催化下转化为谷氨酸，进而进入三羧酸循环以维持其回补反应，为生物合成提供原料并支持能量产生。三阴性乳腺癌中溶质载体家族1成员5和谷氨酰胺酶的表达显著上调，且与较差的预后相关。溶质载体家族1成员5介导的谷氨酰胺摄取对维持三羧酸循环和脂质合成至关重要，而谷氨酰胺酶介导的谷氨酰胺分解则可通过激活核因子E2相关因子2抗氧化通路促进化疗耐药。此外，谷氨酰胺代谢产生的α-酮戊二酸还是表观遗传调控酶的重要辅底物，影响DNA和组蛋白的甲基化状态，从而调控基因表达。同时，线粒体脂肪酸氧化也是三阴性乳腺癌能量供给的重要补充途径。研究表明，三阴性乳腺癌细胞中肉碱棕榈酰转移酶1A的表达上调，使其能够高效利用脂肪酸产生三磷酸腺苷。在化疗耐药的细胞中，脂肪酸氧化活性进一步增强，并通过激活Src激酶和信号转导与转录激活因子3等信号通路，重塑磷脂生物合成，保护线粒体膜，从而对抗凋亡。因此，同时靶向糖酵解、谷氨酰胺分解和脂肪酸氧化，旨在切断肿瘤细胞的能量和物质供应，构成了一个多层次的治疗策略。 氧化应激与凋亡抵抗是三阴性乳腺癌恶性进展和疗效不佳的另一个重要特征。由于线粒体功能障碍、代谢异常活跃以及致癌信号通路的持续刺激，三阴性乳腺癌细胞内的活性氧水平显著高于其他乳腺癌亚型。适度的活性氧水平能够通过激活促生存信号通路促进肿瘤细胞存活，但当活性氧水平超过阈值时，则会损伤线粒体膜和DNA，诱导细胞凋亡。为应对这种持续的高活性氧压力，三阴性乳腺癌细胞进化出强大的抗氧化防御系统，其中最为关键的是核因子E2相关因子2通路和谷胱甘肽系统。三阴性乳腺癌细胞中核因子E2相关因子2呈组成性激活状态，导致谷胱甘肽水平及其与氧化型谷胱甘肽的比率升高，从而有效清除活性氧，抵抗活性氧诱导的凋亡，并对化疗和放疗产生耐受。因此，抑制核因子E2相关因子2或耗竭谷胱甘肽，成为增敏三阴性乳腺癌治疗的潜在策略。在凋亡抵抗方面，三阴性乳腺癌细胞通过多种机制逃逸程序性死亡。其一，是B细胞淋巴瘤2家族蛋白表达失衡，表现为抗凋亡蛋白如Bcl-2、Bcl-xL和Mcl-1的高表达，而促凋亡蛋白如Bax和Bak的表达受抑或活性被抑制。这些抗凋亡蛋白在线粒体外膜上拦截并中和促凋亡蛋白，阻止线粒体外膜通透化和细胞色素c的释放。磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白、丝裂原活化蛋白激酶、信号转导与转录激活因子3等信号通路的过度激活驱动了这些抗凋亡蛋白的高表达。其二，凋亡蛋白抑制因子的表达也显著上调，包括X连锁凋亡抑制蛋白、细胞凋亡抑制蛋白1和细胞凋亡抑制蛋白2。这些蛋白通过其杆状病毒凋亡抑制蛋白重复结构域直接结合并抑制启动型和效应型Caspase，同时利用其RING结构域作为E3泛素连接酶，促进Caspase的蛋白酶体降解。核因子κB信号通路的组成性激活是凋亡蛋白抑制因子转录上调的主要驱动力。高表达的凋亡蛋白抑制因子与患者的不良预后密切相关。因此，靶向Bcl-2家族蛋白的BH3模拟物和靶向凋亡蛋白抑制因子的拮抗剂，在临床前模型中均显示出恢复三阴性乳腺癌细胞凋亡敏感性的巨大潜力。 鉴于线粒体在三阴性乳腺癌发病机制中的核心地位，靶向线粒体功能已成为药物研发的热点，多种靶向药物正处于临床前或临床研究阶段。针对线粒体动力学失衡，开发了一系列小分子抑制剂。例如，线粒体分裂抑制剂1被发现可作为丝裂融合素2的特异性激动剂，促进线粒体融合，抑制细胞增殖、迁移和侵袭，并在动物模型中增敏紫杉醇或多柔比星的疗效。然而，其特异性有限，新一代更选择性的抑制剂如Driptor 1和Driptor1a已显示出更优的潜力。另一种抑制剂dynasore也能增强顺铂在三阴性乳腺癌细胞中的细胞毒性。此外，溴结构域和超末端结构域抑制剂通过下调分裂蛋白和抗凋亡蛋白，促进线粒体融合，发挥抗肿瘤作用。这些靶向分裂的药物不仅能直接抑制肿瘤，还可能减轻化疗药物如多柔比星引起的心脏毒性。针对代谢重编程，多种糖酵解抑制剂如2-脱氧葡萄糖、3-溴丙酮酸等被研究用于抑制三阴性乳腺癌的瓦博格效应，它们可单独或与化疗药物联合，有效抑制肿瘤生长和转移。靶向谷氨酰胺成瘾的谷氨酰胺酶抑制剂如已被证明可抑制细胞增殖、诱导凋亡，并能与紫杉醇、卡铂或哺乳动物雷帕霉素靶蛋白抑制剂等协同增效，在三阴性乳腺癌异种移植模型中显著延缓肿瘤进展。抑制谷氨酰胺转运体的化合物也展现出类似的应用前景。对于增强的脂肪酸氧化，肉碱棕榈酰转移酶1A抑制剂如依托莫西和哌克昔林，能够抑制脂肪酸氧化，选择性抑制三阴性乳腺癌细胞生长，并降低肿瘤干细胞标志物表达。此外，针对氧化应激，核因子E2相关因子2抑制剂如鸦胆子苦素能增加活性氧水平，增强化疗敏感性。而靶向凋亡逃逸的BH3模拟物如维奈托克、那维托克和，以及凋亡蛋白抑制因子拮抗剂如和，都能有效诱导三阴性乳腺癌细胞凋亡，并与多种其他药物产生协同作用。这些多样化的靶向策略共同构筑了一个从代谢、动力学到氧化还原和凋亡的立体攻击网络。 综上所述，线粒体功能紊乱，特别是其动力学失衡、代谢重编程、氧化应激加剧和凋亡逃逸，是三阴性乳腺癌侵袭性、转移性和化疗耐药性的核心驱动因素。靶向线粒体的多种药物在临床前研究中展现出强大的抗肿瘤活性，并与传统化疗药物具有显著的协同效应，为改善三阴性乳腺癌的治疗现状带来了希望。然而，将这一策略成功转化为临床实践仍面临挑战。其中最主要的障碍是三阴性乳腺癌本身的高度异质性，其不同分子亚型(如基底样、间质样和管腔雄激素受体型)在代谢和凋亡特征上存在差异，因此需要识别可靠的预测性生物标志物以实现个性化治疗。同时，靶向线粒体可能存在对正常组织(尤其是心脏、脑和骨骼肌)的潜在毒性。未来研究需着力于开发基于纳米颗粒或抗体偶联药物的靶向递送系统，以提高药物的肿瘤特异性。此外，线粒体功能与肿瘤微环境的动态交互作用，特别是代谢产物如乳酸对免疫细胞的抑制作用，也值得深入探索。将线粒体靶向药物与免疫检查点抑制剂等免疫疗法相结合，可能成为三阴性乳腺癌治疗的新范式。随着线粒体生物学研究的深入和新型药物递送技术的发展，靶向线粒体功能最终有望为三阴性乳腺癌患者带来真正有效的个性化治疗方案。 参考文献： Mishra H, Yadav A, Kushwaha VB, Singh MP. Mitochondrial dynamics: A promising tool for personalized TNBC management. Genes Dis. 2026 Mar 21;13(6):102157. doi: 10.1016/j.gendis.2026.102157. PMID: 42502484; PMCID: PMC13400268. 本文仅供医学学术交流，不构成诊疗建议，不能替代专业医生面诊。详细免责声明请点击菜单栏查阅。

Hepatology[Jour] AND 84[volume] AND 1[issue]  肝脏病学 84卷1期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 Bile acids as the silent harbinger: Early signals of portal hypertension after “successful”Kasai 胆汁酸——沉默的预兆：Kasai术"成功"后的门脉高压早期信号 Sidhu, Guneet Hepatology. 84(1):1-2, July 2026. 2 What’s in a name? Reframing pediatric fatty liver disease in the Era of MASLD 名称之争：代谢相关脂肪性肝病（MASLD）时代儿童脂肪肝疾病的重新定义 Khalid, Mian B.; Ilyas, Sumera I. Hepatology. 84(1):3-4, July 2026. 3 One size does not fit all: Global variability in noninvasive testing for MASLD 一刀切不可取：MASLD无创检测的全球差异性 Erickson, Hanna Hepatology. 84(1):5-6, July 2026. 4 Good vibrations: Using VCTE to predict hepatic decompensation in MASLD 良好的振动：利用振动控制瞬时弹性成像（VCTE）预测MASLD患者的肝脏失代偿 Patel, Krishan S.; Arab, Juan Pablo Hepatology. 84(1):7-8, July 2026. Editorials（社论） 5 FIB-4 turns 20: A lesson of serendipity FIB-4二十周年：一次 serendipity（意外发现）的启示 Sterling, Richard K. Hepatology. 84(1):9-11, July 2026. 6 Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder 肝硬化门静脉血栓——一种血管性而非血栓性疾病 Huang, Xiaoquan; Lisman, Ton Hepatology. 84(1):12-14, July 2026. 7 From sex to size: Rethinking fairness in liver transplantation 从性别到体型：重新思考肝移植中的公平性 Rosenthal, Benjamin E.; Serper, Marina Hepatology. 84(1):15-16, July 2026. 8 Addressing the utility of a novel score for “at-risk” MASH in those with significant obesity 新型评分在显著肥胖人群中"高风险"代谢相关脂肪性肝炎（MASH）中的实用性探讨 Dillon, John F.; Leith, Damien; Brennan, Paul Hepatology. 84(1):17-19, July 2026. Original Articles（论著） Liver Cancer（肝脏肿瘤） 9 Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma 肿瘤部位影响MEKi联合免疫治疗在胆管癌临床前模型中的疗效 Hammons, Jacklyn N.; Warren, Emilie K.; Wittling, Megen C.; More Hepatology. 84(1):20-36, July 2026. 10 RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma RIPPLY1通过靶向TBX19抑制CTNNB1突变型肝细胞癌的肿瘤干细胞特性 Zhangyuan, Guangyan; Yu, Weiwei; Tian, Wenfang; More Hepatology. 84(1):37-56, July 2026. 11 Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules 抗血管生成治疗联合免疫检查点阻断通过高内皮微静脉促进CCR7+CD8+ T细胞进入HCC Tang, Lu; Hou, Yingwen; Di, Tian; More Hepatology. 84(1):57-73, July 2026. Liver Pathobiology（肝脏病理生物学） 12 Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p-pyroptosis axis 肝细胞来源的细胞外囊泡通过miR-153-3p-焦亡轴促进慢性肝病中的内皮去分化 Abad-Jordà, Laia; Andrés-Rozas, María; Martínez-Alcocer, Ana; More Hepatology. 84(1):74-90, July 2026. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门脉高压） 13 Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis 内皮-间充质转化：肝硬化门静脉血栓中可靶向的关键机制 Anton, Aina; Shalaby, Sarah; Botero, María Luisa; More Hepatology. 84(1):91-105, July 2026. 14 Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access MELD 3.0下的性别与体型差异：肝移植可及性中持续存在的差距评估 Tanaka, Tomohiro; Shane, Dan M.; Lai, Jennifer C. Hepatology. 84(1):106-116, July 2026. Pediatrics（儿科学） 15 Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia 血清胆汁酸水平可预测胆道闭锁Kasai术后成功患者门脉高压及高风险食管静脉曲张的发生 Grimaud, Emilie; Gardin, Antoine; Ackermann, Oanez; More Hepatology. 84(1):117-128, July 2026. 16 Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN 利用脂肪性肝病框架重新分类儿童非酒精性脂肪性肝病（NAFLD）：来自NASH CRN的多中心回顾性研究 Lam, Tin Bo Nicholas; Yates, Katherine P.; Noon, Sheila L.; More Hepatology. 84(1):129-142, July 2026. Steatohepatitis（脂肪性肝炎） 17 KLF9 drives intermittent hypoxia-induced MASLD by suppressing the NR4A1–p38 MAPK hepatic metabolic axis KLF9通过抑制NR4A1–p38 MAPK肝脏代谢轴驱动间歇性缺氧诱导的MASLD Hua, Hongting; Wang, Dong; He, Lanqiaofeng; More Hepatology. 84(1):143-160, July 2026. 18 Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study MASLD无创检测的全球表现：来自G-MASLD研究的洞察 Younossi, Zobair M.; de Avila, Leyla; Petta, Salvatore; More Hepatology. 84(1):161-174, July 2026. 19 Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease 振动控制瞬时弹性成像与组织学在预测代谢功能障碍相关脂肪性肝病肝脏相关事件中的头对头比较 Zhang, Yangyue; Lee, Hye Won; Lin, Huapeng; More Hepatology. 84(1):175-190, July 2026. 20 Development and validation of a noninvasive score for at-risk metabolic dysfunction–associated steatohepatitis in individuals with obesity undergoing bariatric surgery 针对肥胖减重手术人群中"高风险"代谢功能障碍相关脂肪性肝炎的无创评分的开发与验证 Huang, Xin; Zhu, Tao; Li, Shumin; More Hepatology. 84(1):191-203, July 2026. Original Articles（论著） Steatohepatitis（脂肪性肝病） 21 Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study MASLD中纤维化、临床事件及死亡率的预测因素：来自Global-MASLD研究的数据 Younossi, Zobair M.; de Avila, Leyla; Petta, Salvatore; More Hepatology. 84(1):204-215, July 2026. Viral Hepatitis（病毒性肝炎） 22 HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner 乙肝病毒（HBV）以丙酮酸依赖方式通过活性氧生成诱导肝纤维化 Duan, Xiaoqiong; Li, Shasha; Li, Qingyuan; More Hepatology. 84(1):216-232, July 2026. 23 IL1β signaling mediates the interaction between hepatitis B and C viruses IL1β信号介导乙型与丙型肝炎病毒之间的相互作用 Zhang, Fan; Zhao, Yuanyuan; Bian, Lu; More Hepatology. 84(1):233-250, July 2026. Reviews（综述） 24 Reprogramming macrophages to treat liver diseases 巨噬细胞重编码治疗肝脏疾病 Simón-Codina, Blanca; Cacho-Pujol, Júlia; Moles, Anna; More Hepatology. 84(1):251-272, July 2026. 25 Mechanisms coupling lipid droplets to MASLD pathophysiology 脂滴与MASLD病理生理偶联的机制 Reid, Mari V.; Fredickson, Gavin; Mashek, Douglas G. Hepatology. 84(1):273-291, July 2026. 26 Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic 新一代抗病毒药物与肥胖流行时代的肝癌预防 Suzuki, Hiroyuki; Fujiwara, Naoto; Singal, Amit G.; More Hepatology. 84(1):292-320, July 2026. Special Article（专题论著） 27 Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration 无创检测：在超越活检的层面确立代谢功能障碍相关脂肪性肝炎的有效性——来自美国食品药品监督管理局肝病与营养部的当前观点 Anania, Frank A.; Hager, Rebecca; Higgins, Karen; More Hepatology. 84(1):321-327, July 2026. Correspondence（读者来信） 28 Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma 致编辑信：重新评估RIPPLY1-TBX19轴在CTNNB1突变型肝细胞癌中的临床相关性 Zhang, Xiang; Gong, Hui; Gu, Kaikai; More Hepatology. 84(1):E1-E2, July 2026. 29 Letter to the Editor: Nuances in POCUS-guided hemodynamic assessment in cirrhosis 致编辑信：POCUS引导下肝硬化血流动力学评估中的细微之处 Koratala, Abhilash; Argaiz, Eduardo R. Hepatology. 84(1):E3-E4, July 2026. 30 Reply: Nuances in POCUS-guided hemodynamic assessment in cirrhosis 回复：POCUS引导下肝硬化血流动力学评估中的细微之处 Premkumar, Madhumita; Kajal, Kamal Hepatology. 84(1):E5-E6, July 2026. 31 Letter to the Editor: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children? 致编辑信：PNPLA3悖论——基因型是否改变MASLD框架在儿童中的临床实用性？ Liu, Boyan; Li, Heran Hepatology. 84(1):E7-E8, July 2026. 32 Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children? 回复：PNPLA3悖论——基因型是否改变MASLD框架在儿童中的临床实用性？ Lam, Tin Bo Nicholas; Goyal, Nidhi P.; Newton, Kimberly P.; More Hepatology. 84(1):E9-E10, July 2026. 33 Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure 致编辑信：核苷（酸）类似物治疗后HBsAg水平的变化特征对实现功能性治愈至关重要 Tang, Qiao; Hu, Peng Hepatology. 84(1):E11-E12, July 2026. 34 Letter to the Editor: Comments on the Study—Body size disparities limit women’s access to liver transplantation under the MELD 3.0 scoring system 致编辑信：对"体型差异限制女性在MELD 3.0评分体系下获得肝移植机会"研究的评论 He, Jiahang; Xie, Qing; Cao, Zhujun Hepatology. 84(1):E13, July 2026. 35 Letter to the Editor: Clarifying validation and statistical aspects of AI-based risk prediction in liver disease 致编辑信：澄清AI基于风险预测在肝病中的验证与统计学问题 Liu, Jing; Zhang, Guo-Ming Hepatology. 84(1):E14-E15, July 2026. 36 Reply: Clarifying validation and statistical aspects of AI-based risk prediction in liver disease 回复：澄清AI基于风险预测在肝病中的验证与统计学问题 Zhang, Peng; Su, Grace L. Hepatology. 84(1):E16-E17, July 2026. 37 Letter to the Editor: Clarifying endothelial specificity and hemodynamic coupling of the miR-153-3p–pyroptosis axis 致编辑信：澄清miR-153-3p–焦亡轴的内皮特异性与血流动力学偶联 Weng, Dandan Hepatology. 84(1):E18-E19, July 2026. 38 Letter to the Editor: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics 致编辑信：安慰剂漂移、剂量异质性与赢者诅咒——重新评估MASH治疗药物的层级 Philips, Cyriac Abby; Oommen, Tharun Tom; Ahamed, Rizwan Hepatology. 84(1):E20-E21, July 2026. 39 Reply: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics 回复：安慰剂漂移、剂量异质性与赢者诅咒——重新评估MASH治疗药物的层级 Souza, Matheus; Huang, Daniel Q.; Loomba, Rohit Hepatology. 84(1):E22-E23, July 2026. 40 Letter to the Editor: Interpreting the clinical decision value of glycomic-based models for early HCC detection in CHB 致编辑信：解读糖组学模型在CHB早期HCC检测中的临床决策价值 Jiang, Qing-Bao; Zhang, Guo-Ming Hepatology. 84(1):E24-E25, July 2026. 41 Letter to the Editor: From weight to waist—Refining fibrosis prediction in the Global MASLD cohort 致编辑信：从体重到腰围——优化Global MASLD队列中的纤维化预测 Zeng, Hong; Huang, Xi Hepatology. 84(1):E26-E27, July 2026. 42 Reply: From weight to waist—Refining fibrosis prediction in the Global MASLD cohort 回复：从体重到腰围——优化Global MASLD队列中的纤维化预测 Stepanova, Maria; Younossi, Zobair M. Hepatology. 84(1):E28-E29, July 2026. Hepatology[Jour] AND 84[volume] AND 2[issue]  肝脏病学 84卷2期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 PSC’s itch is worth scratching: Pruritus can be more than a symptom 原发性硬化性胆管炎瘙痒值得重视：瘙痒并非单纯伴随症状 Yigit Yazarkan Hepatology. August 2026: 84(2):329-330 2 The weight of progress: Why dynamic weight trajectories matter in MASLD 体重变化的临床意义：代谢相关脂肪性肝病中动态体重轨迹的价值 Guneet Sidhu Hepatology. August 2026: 84(2):331-332 3 The liver joins the CKM conversation: Fibrosis risk across the cardiometabolic spectrum 肝脏纳入心脏代谢疾病评估：横跨心脏代谢疾病谱的肝纤维化风险 Omar Albhaisi, Juan Pablo Arab Hepatology. August 2026: 84(2):333-334 4 Pizza versus Pi*ZZ: The metabolic amplifiers in alpha-1 antitrypsin deficiency 饮食与基因交互：α1-抗胰蛋白酶缺乏症的代谢放大因素 John Grady, Juan Pablo Arab Hepatology. August 2026: 84(2):335-336 Editorials（社论） 5 Stains in primary biliary cholangitis: Untangling promise from bias 原发性胆汁性胆管炎相关染色标志物：区分临床价值与研究偏倚 Therese Bittermann, Charles E. Leonard Hepatology. August 2026: 84(2):337-339 6 Multiomics and machine learning in cholangiocarcinoma: A paradigm shift toward molecular subtyping and precision therapy 多组学与机器学习在胆管癌中的应用：迈向分子分型与精准治疗的范式革新 Meng Xu, Ju-Seog Lee Hepatology. August 2026: 84(2):340-342 7 A targeted liver cancer therapy independent of immune checkpoint block 不依赖免疫检查点抑制剂的肝癌靶向治疗方案 Bangyan L. Stiles Hepatology. August 2026: 84(2):343-345 8 Alcohol use dominates determining liver-related events in steatotic liver disease: Rethinking the role of metabolic dysfunction 饮酒是脂肪性肝病肝脏不良事件的核心诱因：重新审视代谢功能障碍的作用 Luis Antonio Díaz, Winston Dunn, Ashwani K. Singal Hepatology. August 2026: 84(2):346-348 9 Shedding new light on the chicken-and-egg dilemma of hepatitis delta virus (HDV) replication initiation 厘清丁型肝炎病毒复制起始的因果先后难题 Julie Lucifora, Francesco Negro Hepatology. August 2026: 84(2):349-352 Original Articles: Immune-Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性肝病、药物性肝损伤与胆道疾病） 10 Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study 原发性硬化性胆管炎瘙痒高发且持续存在，瘙痒程度与疾病严重度相关：一项多中心前瞻性观察研究 Nasir Hussain, Rodrigo V. Motta, Usha Gungabissoon, Linda Casillas, Sumanta Mukherjee, Andrea Ribeiro, Megan M. Mclaughlin, Kaitlin Hagan, Khushpreet Bhandal, Penelope Rogers, Martine Walmsley, James Ferguson, Andreas E. Kremer, Emma L. Culver, Palak J. Trivedi Hepatology. August 2026: 84(2):353-366 11 Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study 他汀类药物使用与原发性胆汁性胆管炎患者肝失代偿的关联：模拟目标临床试验研究 Jonggi Choi, Junqing Xu, Vy H. Nguyen, Eric Przybyszewski, Daniel S. Pratt, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung Hepatology. August 2026: 84(2):367-377 Original Articles: Liver Cancer（论著：肝脏肿瘤） 12 NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma NEK7介导EGFR第1070位丝氨酸磷酸化诱发肝细胞癌的仑伐替尼获得性耐药 Qibo Huang, Weijian Wang, Qianyun Ge, Dafeng Xu, Renshun Dong, Ruizhi Chang, Xing Wu, Jie Mo, Chen Su, Deng Ning, Qiumeng Liu, Huifang Liang, Guihua Wang, Jin Chen, Xifeng Fu, Xiaoping Chen, Junnan Liang, Bixiang Zhang Hepatology. August 2026: 84(2):378-395 13 Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target 多组学联合机器学习鉴定胆管癌独特分子亚型并筛选TNK1为治疗靶点 Dong-Gi Mun, Erik Jessen, Jennifer L. Tomlinson, Danielle Carlson, Rohit Budhraja, Roberto Alva-Ruiz, Amro Abdelrahman, Ryan Watkins, Lindsey Gregory, Chantal McCabe, Chen Wang, Rondell P. Graham, Kathryn Woods, Martin Golkowski, Marshall Baker, Gregory J. Gores, Sumera I. Ilyas, Caitlin Conboy, Ellen L. Larson, Jack W. Sample, Enis H. Ozmert, Richard K. Kandasamy, Mitesh J. Borad, Lewis Roberts, Joshua Andersen, Akhilesh Pandey, Rory L. Smoot Hepatology. August 2026: 84(2):396-410 14 Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy 病毒性与代谢相关脂肪性肝病相关肝癌肠道菌群存在差异，但代谢组特征趋同，共同影响联合免疫治疗疗效 Pei-Chang Lee, Chi-Jung Wu, Ya-Wen Hung, Chieh-Ju Lee, Hsien-Chen Mon, Chen-Ta Chi, I-Cheng Lee, Yu-Lun Kuo, Shih-Hsuan Chou, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang Hepatology. August 2026: 84(2):411-423 15 Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles 载聚肌胞苷酸脂质纳米颗粒可有效抑制肝脏原发及转移性肿瘤 Yingluo Liu, Xinyi Wang, Nishta Krishnan, Timothy Hsiao, Yichun Ji, Kota Kaneko, Marcos G. Teneche, Peter D. Adams, Elina Zuniga, Susan M. Kaech, Liangfang Zhang, Gen-Sheng Feng Hepatology. August 2026: 84(2):424-439 16 Genomic and transcriptomic profiling of hepatocellular carcinoma in patients with Fontan-associated liver disease 丰坦手术相关性肝病合并肝细胞癌的基因组与转录组图谱分析 Taiji Yamazoe, Eiji Kakazu, Michitaka Matsuda, Masaaki Mino, Taizo Mori, Sachiyo Yoshio, Yuriko Tsutsui, Takashi Motomura, Shinji Itoh, Koichiro Haruki, Kenei Furukawa, Shinichiro Yamada, Takeshi Takamoto, Takehiro Noda, Hidetoshi Eguchi, Kiyoshi Hasegawa, Yuji Morine, Toru Ikegami, Tomoharu Yoshizumi, Tatsuya Kanto Hepatology. August 2026: 84(2):440-452 17 Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy 深度学习辅助MRI肿瘤影像组学动态特征预测免疫治疗联合肝切除肝细胞癌患者的病理完全缓解 Shi-Qi Zhou, Lu-Na Wang, Li-Fang Wu, Li-Yu Sun, Yu-Chen Yang, Zi-Yue Yang, Zi-Yi Wang, Tian He, Fei Li, Ling-Li Chen, Hui Li, Xiao-Dong Zhu, Ying-Hao Shen, Cheng Huang, Yuan Ji, Qiang Gao, Jian Zhou, Jia Fan, Yong-Jun Chen, Tian-Qiang Song, Bin Xu, Hui-Chuan Sun Hepatology. August 2026: 84(2):453-468 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 18 Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation 肝细胞FoxO1表观遗传抑制破坏肝脏局部免疫稳态并诱发肝炎症 Zhigang Lei, Yu Wu, Weijie Xue, Dongmei Zhu, Junyao Shen, Chenxu Mao, Ziling Wang, Chuanhong Huang, Yuxin Zhang, Jifeng Zhu, Lei Xu, Yalin Li, Xiujun Zhang, Shouguo Liu, Xiaojun Chen, Chunyan Ye, Sha Zhou, Chuan Su Hepatology. August 2026: 84(2):469-486 19 CXCR6 defines a distinct resident state in γδ T cells for protecting from liver cirrhosis CXCR6标记具有独特定居表型的γδT细胞，可抵御肝硬化进展 Jiahao Ji, Zhitao Chen, Wenjing He, Yanxu Chen, Dongmei Ye, Yingqian Zhong, Xiaomin Shi, Xiaojun Ouyang, Zhimin Zeng, Qianyu Ye, Xiaoshun He, Zhinan Yin, Jianlei Hao, Yifang Gao Hepatology. August 2026: 84(2):487-502 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 20 Differential associations of cardiometabolic risk factors with liver-related events by alcohol consumption category: Results from a large population-based study 不同饮酒分层下心代谢危险因素与肝脏不良事件的差异性关联：一项大样本人群研究 Hongliang Xue, Liqing Wang, Yuankai Wu, Yingxin Liao, Shijia Wang, Ailan Chen, Sun On Chan, Wenhua Ling, Xu Chen, Chao Yu Hepatology. August 2026: 84(2):503-513 21 Association between longitudinal weight change and clinical outcome in individuals with MASLD 代谢相关脂肪性肝病患者纵向体重变化与临床预后的相关性 Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Philip Noel Newsome, Jian-Gao Fan, Michelle Lai, Laurent Castéra, Céline Fournier-Poizat, Hye Won Lee, Grace Lai-Hung Wong, Grazia Pennisi, Masato Yoneda, Ying Shang, Angelo Armandi, Marc de Saint-Loup, Clemence M. Canivet, Kevin Kim-Jun Teh, Amon Asgharpour, Rocio Gallego-Durán, Elba Llop, Carmen Lara-Romero, Mandy Sau-Wai Chan, Mirko Zoncape, Huapeng Lin, Wen-Yue Liu, Giovanni Targher, Christopher D. Byrne, Vincent Wai-Sun Wong, Ming-Hua Zheng, Hepatology. August 2026: 84(2):514-528 22 Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD 心肾代谢综合征与代谢相关脂肪性肝病肝纤维化进展及肝脏不良事件风险的关联 Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victor de Lédinghen, Laurent Castéra, Arun J. Sanyal, George Boon-Bee Goh, Philip Noel Newsome, Jian-Gao Fan, Michelle Lai, Céline Fournier-Poizat, Hye Won Lee, Grace Lai-Hung Wong, Angelo Armandi, Ying Shang, Grazia Pennisi, Elba Llop, Masato Yoneda, Marc de Saint-Loup, Clemence M. Canivet, Paloma Carrillo-Fernandez, Carmen Lara-Romero, Rocio Gallego-Durán, Amon Asgharpour, Kevin Kim-Jun Teh, Mandy Sau-Wai Chan, Huapeng Lin, Wen-Yue Liu, Giovanni Targher, Christopher D. Byrne, Vincent Wai-Sun Wong, Ming-Hua Zheng, Hepatology. August 2026: 84(2):529-541 23 Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency α1-抗胰蛋白酶缺乏症中遗传与代谢危险因素的协同放大效应 Christina Schrader, Malin Fromme, Paul Ellis, Audrey Payancé, Mattias Mandorfer, Jan Stolk, Bart van Hoek, Katrine H. Thorhauge, Monica Pons, Marc Miravitlles, Guido Stirnimann, Sona Frankova, Jan Sperl, Andreas E. Kremer, Katharina Remih, Emily K. Weber, Lorenz Balcar, Annelot D. Sark, Benedikt Schaefer, Joanna Chorostowska-Wynimko, Elmar Aigner, Sophie Gensluckner, Heike Bantel, Jef Verbeek, Zoe Mariño, Rohit Loomba, Heinz Zoller, Michael Trauner, Joan Genesca, Virginia Clark, Aleksander Krag, Noel G. McElvaney, William J. Griffiths, Alice M. Turner, Pavel Strnad Hepatology. August 2026: 84(2):542-558 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 24 CDK8 and CDK19 Mediator kinases are required for hepatitis delta virus replication 中介激酶CDK8与CDK19是丁型肝炎病毒复制的必需分子 Angga Prawira, Mattis Hilleke, Mengqian Chen, Igor B. Roninson, Ralf Bartenschlager, Stephan Urban, Yi Ni Hepatology. August 2026: 84(2):559-572 Reviews（综述） 25 Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached? 门脉性肺动脉高压诊疗尚未满足的临床需求：当前研究进展综述 Michael J. Krowka, Hilary M. DuBrock, Sarah Raevens, Michael B. Fallon Hepatology. August 2026: 84(2):573-581 26 Getting to HBV cure—Will new biomarkers help? 迈向乙型肝炎治愈：新型生物标志物能否提供助力？ Jordan J. Feld, Adam J. Gehring, Fabien Zoulim Hepatology. August 2026: 84(2):582-600 Special Articles（专题论著） 27 A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF 多学会关于门窦血管病变/非肝硬化性门脉高压新统一定义与诊断标准的共识声明 Virginia Hernandez-Gea, Valerie Paradis, Maha Guindi, Venancio A.F. Alves, Amal Aqul, Eira Cerda, Sarwa Darwish Murad, Prasenjit Das, Angelo Di Giorgio, Luiz A.R. de Freitas, Tassos Grammatikopoulos, Kenichi Harada, Nelia Hernandez, Samar H. Ibrahim, Sanjay Kakar, Saul Karpen, David E. Kleiner, Necati Ormeci, Xiaolong Qi, Puja Sakhuja, Maria Isabel Schinoni, Romil Saxena, Alexandre Sayadi, Akash Shukla, Dina G. Tiniakos, Elizabeth Verna, Kerry Wong, Laure Elkrief, Christine Sempoux, Theo Heller, Pierre-Emmanuel Rautou Hepatology. August 2026: 84(2):601-616 28 Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH Ⅱb期临床试验证实依鲁西佛明在不同PNPLA3基因型代谢相关脂肪性肝炎人群中疗效稳定 Naga Chalasani, Erik J. Tillman, Sonja K. Billes, Timothy Rolph, Mazen Noureddin Hepatology. August 2026: 84(2):617-620 Correspondence（通信） 29 Letter to the Editor: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy? 致编者信：粪便乙酸盐是否可作为全病因肝癌免疫治疗疗效预测标志物？ Zhou Zhao, Jian Sun, Qiuhong You, Zhixian Lan, Yinghong Zhu Hepatology. August 2026: 84(2):E30-E31 30 Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy? 回复：粪便乙酸盐是否可作为全病因肝癌免疫治疗疗效预测标志物？ Pei-Chang Lee, Yi-Hsiang Huang Hepatology. August 2026: 84(2):E32-E33 31 Letter to the Editor: Survival analysis pitfalls in MASLD: Proportional hazards, immortal time, and follow-up discrepancies 致编者信：代谢相关脂肪性肝病生存分析常见误区：比例风险、永生时间与随访偏差 Jian Huang Hepatology. August 2026: 84(2):E34-E35 32 Reply: Survival analysis pitfalls in MASLD—Proportional hazards, immortal time, and follow-up discrepancies 回复：代谢相关脂肪性肝病生存分析常见误区——比例风险、永生时间与随访偏差 Yu Shi, Ruoqi Zhou, Yuanjie Pang, Vincent Wai-Sun Wong, Ming-Hua Zheng Hepatology. August 2026: 84(2):E36-E37 33 Letter to the Editor: Beyond Semantics—Acknowledging diagnostic differences between NAFLD and MASLD 致编者信：不止命名差异——正视NAFLD与MASLD的诊断区分要点 Giovani Schulte Farina, Jonathan Soldera Hepatology. August 2026: 84(2):E38-E39 34 Reply: Beyond semantics—Acknowledging diagnostic differences between NAFLD and MASLD 回复：不止命名差异——正视NAFLD与MASLD的诊断区分要点 Madalina-Gabriela Indre, Federico Ravaioli Hepatology. August 2026: 84(2):E40-E41 35 Letter to the editor: Deep learning and digital pathology for HCC prediction in steatotic liver disease 致编者信：深度学习与数字病理用于脂肪性肝病肝癌发生风险预测 Luisa Giudice, Stefano Granieri, Stefania Galassi, Sante De Santis, Emmanuel Pio Pastore Hepatology. August 2026: 84(2):E42-E43 36 Reply: Deep learning and digital pathology power prediction of HCC development in steatotic liver disease 回复：深度学习联合数字病理可精准预测脂肪性肝病患者肝癌发病风险 Takuma Nakatsuka, Ryosuke Tateishi, Masaya Sato, Kazuhiko Koike Hepatology. August 2026: 84(2):E44-E45 Errata（勘误） 37 Erratum: Reciprocal regulation between forkhead box M1/NF-κB and methionine adenosyltransferase 1A drives liver cancer 勘误：FOXM1/NF-κB与甲硫氨酸腺苷转移酶1A相互调控促进肝癌发生 Yuan Li, Liqing Lu, Jian Tu, Jing Zhang, Ting Xiong, Wei Fan, Jiaohong Wang, Meng Li, Yibu Chen, Justin Steggerda, Hui Peng, Yongheng Chen, Tony WH Li, Zhi-Gang Zhou, José M Mato, Ekihiro Seki, Ting Liu, Heping Yang, Shelly C. Lu Hepatology. August 2026: 84(2):E46-E47 38 Erratum: AlphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma 勘误：αB-晶状体蛋白结合14-3-3ζ诱导肝细胞癌上皮间质转化与索拉非尼耐药 Huang Xiao-Yong, Ke Ai-Wu, Shi Guo-Ming, Zhang Xin, Zhang Chi, Shi Ying-Hong, Wang Xiao-Ying, Ding Zhen-Bin, Xiao Yong-Sheng, Yan Jun, Qiu Shuang-Jian, Fan Jia, Zhou Jian Hepatology. August 2026: 84(2):E48-E49 39 Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis 勘误：美国肝病研究协会慢加急性肝衰竭与重症肝硬化患者管理临床实践指南 Constantine J. Karvellas, Jasmohan S. Bajaj, Patrick S. Kamath, Lena Napolitano, Jacqueline G. O’Leary, Elsa Solà, Ram Subramanian, Florence Wong, Sumeet K. Asrani Hepatology. August 2026: 84(2):E50-E50 40 Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D 勘误：非侵入性评估非酒精性脂肪性肝病合并2型糖尿病患者肝病严重程度 Grazia Pennisi, Marco Enea, Vincenzo Falco, Guruprasad P. Aithal, Naaventhan Palaniyappan, Yusuf Yilmaz, Jerome Boursier, Christophe Cassinotto, Victor de Lédinghen, Wah Kheong Chan, Sanjiv Mahadeva, Peter Eddowes, Philip Newsome, Thomas Karlas, Johannes Wiegand, Vincent Wai-Sun Wong, Jörn M. Schattenberg, Christian Labenz, Won Kim, Myoung Seok Lee, Monica Lupsor-Platon, Jeremy F. Cobbold, Jian-Gao Fan, Feng Shen, Katharina Staufer, Michael Trauner, Rudolf Stauber, Atsushi Nakajima, Masato Yoneda, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Ming-Hua Zheng, Calogero Cammà, Quentin M. Anstee, Ferenc E. Mózes, Michael Pavlides, Salvatore Petta Hepatology. August 2026: 84(2):E51-E51 Retraction（撤稿声明） 41 Retraction: HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD 撤稿声明：热休克蛋白72结合过氧化物还原蛋白6去泛素化线粒体PINK1，激活线粒体自噬改善代谢相关脂肪性肝病 Yong Rao, Rui Su, Wen-jie Cao, Yue Chen, Shu-heng Huang, Jun-jie Wu, Darren C. Henstridge, Lin-sheng Huang, Jin Liu, Fei-fei Liu, Zhong-ping Jiang, Cong-jun Xu, Zhi-shu Huang, Ji-ming Ye, Ling Huang Hepatology. August 2026: 84(2):E52-E52 Hepatology[Jour] AND 84[volume] AND 3[issue]  肝脏病学 84卷3期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（《肝脏病学》重点导读） 1 The road less traveled: Mapping the complex trajectories of PSC‑IBD 少有人走的路：原发性硬化性胆管炎‑炎症性肠病复杂病程轨迹解析 Mian B. Khalid Hepatology. September 2026: 84(3):621‑622 2 One cancer, four personalities: Transcriptomic signatures reveal molecular subtypes of advanced biliary tract cancer 一种肿瘤，四种表型：转录组特征揭示晚期胆道癌分子亚型 Muhammed Dogukan Aksu Hepatology. September 2026: 84(3):623‑624 3 Hepatic footprint of emerging antihyperglycemic therapies 新型降糖治疗的肝脏效应 P. Vineeth Daniel Hepatology. September 2026: 84(3):625‑626 4 No prescription needed: Remote nutrition care linked to fewer liver events 无需处方：远程营养干预可减少肝脏相关不良事件 Leandro Sierra, Juan Pablo Arab Hepatology. September 2026: 84(3):627‑628 Fellows' Corner（青年学者园地） 5 Fellows’ Corner 青年学者园地 Somaya Albhaisi Hepatology. September 2026: 84(3):629‑630 Editorials（社论） 6 Population‑level screening for liver disease: Opportunities and challenges 人群水平肝脏疾病筛查：机遇与挑战 Pedro Ochoa‑Allemant, Marina Serper Hepatology. September 2026: 84(3):631‑633 7 Two decades of hepatitis E in solid organ transplantation: From endemic insight to unresolved therapeutic questions 实体器官移植中戊型肝炎二十年：从流行特征到尚未解决的治疗难题 Patrick Behrendt, Christoph Neumann‑Haefelin Hepatology. September 2026: 84(3):634‑637 8 Interpreting surgical associations in primary sclerosing cholangitis: Caution in clinical messaging 解读原发性硬化性胆管炎的手术相关性：临床解读需审慎 Bregje Mol, Palak J. Trivedi Hepatology. September 2026: 84(3):638‑640 Original Articles: Immune‑Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性疾病、药物性肝损伤与胆道疾病） 9 Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes 他汀类药物通过重编程囊胆管上皮细胞代谢、恢复线粒体生物能量功能抑制多囊肝进展 Enara Markaide, Laura Izquierdo‑Sanchez, Irene Olaizola, Josu Urretabizkaia‑Garmendia, Mikel Ruiz de Gauna, Xabier Buqué, Irune Lasa‑Elosegi, Ainhoa Lapitz, Thomas Bais, Beatriz Val, Pedro M. Rodrigues, Rui E. Castro, Maria J. Perugorria, Luis Bujanda, Ron Gansevoort, Joost P.H. Drenth, Patricia Aspichueta, Jesus M. Banales Hepatology. September 2026: 84(3):641‑657 10 Understanding hepatopancreatobiliary cancer risks in a population‑based primary sclerosing cholangitis–inflammatory bowel disease cohort 基于人群的原发性硬化性胆管炎‑炎症性肠病队列肝胆胰肿瘤风险研究 Kristel K. Leung, Wenbin Li, Bettina Hansen, Aliya Gulamhusein, Lauren Lapointe‑Shaw, Amanda Ricciuto, Eric I. Benchimol, Jennifer A. Flemming, Gideon M. Hirschfield Hepatology. September 2026: 84(3):658‑671 Original Articles: Liver Cancer（论著：肝脏肿瘤） 11 GPC3‑based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses 基于GPC3的环状RNA疫苗通过激活适应性免疫应答抑制肝细胞癌进展 Yifan Jiang, Yu Li, Tong Wu, Linping Cao, Guangming Xu, Jiwei Liu, Chenguang Hua, Chaofeng Ding, Beng Yang, Rongliang Tong, Diyu Chen, Jian Wu Hepatology. September 2026: 84(3):672‑689 12 Laser‑activated nanoparticles rewire tumor microenvironment enhancing PD‑1 blockade and T cell response in cholangiocarcinoma 激光激活纳米颗粒重编程肿瘤微环境增强胆管癌PD‑1阻断疗效与T细胞应答 Mirko Minini, Giulio Avveduto, Sonia Becharef, Marie Meunier‑Thaens, Bouchra Lekbaby, Maria Perez‑Lazon, Alice Machado, Thomas Guilbert, Julie Lesieur, Gilles Renault, Sara Ceccacci, Ida Chiara Guerrera, Christophe Klein, Jérémy Augustin, Rana Bazzi, Stephane Roux, Jonathan Pol, Emmanuel Donnadieu, Florence Gazeau, Laura Fouassier Hepatology. September 2026: 84(3):690‑707 13 FXR splicing by SF3B3 promotes MYC‑driven hepatocarcinogenesis SF3B3介导FXR可变剪接促进MYC驱动的肝细胞癌发生 Xue Wang, Jiahua Luo, Lifeng Han, Tong Xu, Haichuan Wang, Mingzhe Zhang, Gen Li, Xichuan Li, Weihua Zhang, Youcai Zhang Hepatology. September 2026: 84(3):708‑725 14 Biology‑driven stratification of advanced biliary tract cancer treated with nab‑paclitaxel plus gemcitabine–cisplatin: A prospective observational cohort study 白蛋白结合型紫杉醇联合吉西他滨‑顺铂治疗晚期胆道癌的生物学分层：一项前瞻性观察队列研究 Seonjeong Woo, Beodeul Kang, Sung Hwan Lee, Jung Sun Kim, Haeyoun Kang, Seok Jeong Yang, Chansik An, Gwangil Kim, Gae Hoon Jo, Chang‑Il Kwon, Min Je Sung, Suk Pyo Shin, Sanghoon Jung, Sohyun Hwang, Chan Kim, Hong Jae Chon Hepatology. September 2026: 84(3):726‑739 15 Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling 多灶性肝内胆管癌卫星灶与肝内转移：预后价值及基因组特征分析 Tao Wei, Zhi‑Jie Ma, Shouliang Guo, Matthew Weiss, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, Shishir K. Maithel, Carlo Pulitano, Todd W. Bauer, Feng Shen, George A. Poultsides, Oliver Soubrane, Guillaume Martel, Bas Groot Koerkamp, Itaru Endo, Tingbo Liang, Yi Lyu, Timothy M. Pawlik, Xu‑Feng Zhang, Hepatology. September 2026: 84(3):740‑755 16 Long‑term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real‑world study 阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的远期预后：一项真实世界研究 Francesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, Fabio Marra, Caterina Vivaldi, Andrea Dalbeni, Francesca Romana Ponziani, Andrea Palloni, Francesca Bergamo, Lorenza Rimassa, Lorenzo Lani, Piera Federico, Gianluca Svegliati‑Baroni, Luca Ielasi, Chiara Mazzarelli, Stefania De Lorenzo, Rodolfo Sacco, Mariangela Bruccoleri, Ciro Celsa, Alessio Mastro, Gianluca Masi, Alessandra Auriemma, Leonardo Stella, Pierluigi Toniutto, Rosanna Villani, Sara Lonardi, Tiziana Pressiani, Fabio Piscaglia, Hepatology. September 2026: 84(3):756‑768 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 17 Hepatic STEAP4 promotes liver regeneration by regulating lysosomal iron homeostasis and membrane integrity in acetaminophen‑induced liver injury 肝脏STEAP4通过调控溶酶体铁稳态及膜完整性促进对乙酰氨基酚肝损伤后的肝再生 Peng Cao, Mengwei Niu, Hualong Zhu, Chen Zhang, Hao Zhu, Hangfei Xu, Wanqing Liu, Hong‑Min Ni, Wen‑Xing Ding Hepatology. September 2026: 84(3):769‑784 18 ECM1 produced by hepatic stellate cells serves as a gatekeeper of liver homeostasis in hepatic fibrosis 肝星状细胞分泌ECM1是肝纤维化中肝脏稳态的关键调控因子 Aiting Yang, Xuzhen Yan, Yiwen Wang, Qi Han, Xiaofei Tong, Shuyan Chen, Xinyu Zhao, Wei Chen, Jidong Jia, Detlef Schuppan, Hong You Hepatology. September 2026: 84(3):785‑804 Original Articles: Liver Failure/Cirrhosis/Portal Hypertension（论著：肝衰竭/肝硬化/门静脉高压） 19 LiverRisk score (LRS) predicts long‑term liver‑related outcomes in a cohort of Veterans without evidence of liver disease LiverRisk评分（LRS）可预测无肝病证据退伍军人队列的长期肝脏相关预后 Ruben Hernaez, Yan Liu, Miquel Serra‑Burriel, Kavish R. Patidar, Adrià Juanola, Isabel Graupera, Elisa Pose, Núria Fabrellas, Avegail G. Flores, Jennifer R. Kramer, Fasiha Kanwal, Pere Gines Hepatology. September 2026: 84(3):805‑816 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 20 Real‑world impact of AUD pharmacotherapy on healthcare utilization, cost, and cost‑effectiveness in the United States 美国酒精使用障碍药物治疗对医疗资源利用、费用及成本效益的现实影响 Chi M. Nguyen, Hanna L. Blaney, Jing Su, Shihui Jiang, Yang Li, Yining Li, Samer Gawrieh, Wanzhu Tu, Suthat Liangpunsakul Hepatology. September 2026: 84(3):817‑832 21 Repurposing Resmetirom suppresses MASH‑associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1‑mediated metabolic reprogramming and immunosuppression Resmetirom老药新用抑制MASH相关肝细胞癌：MDK/LRP1介导代谢重编程与免疫抑制的机制研究 Vanilla Xin Zhang, Tina Suoangbaji, Yu‑Man Tsui, Karen Man‑Fong Sze, Eva Lee, Lu Tian, Jingyi Lu, Huan Deng, Abdullah Husain, Charry Shuk‑Ching Hui, Joyce Man‑Fong Lee, Daniel Wai‑Hung Ho, Irene Oi‑Lin Ng Hepatology. September 2026: 84(3):833‑850 22 Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta‑analysis of data from 5.3 million patients with type 2 diabetes mellitus 新型降糖药物对肝脏并发症的影响：基于530万2型糖尿病患者数据的系统综述与Meta分析 Jiwon Yang, Yeongseok Hwang, Jin‑Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim Hepatology. September 2026: 84(3):851‑869 23 Reduced risk of liver‑related events among patients receiving individualized nutrition‑focused remote care in the United States 美国接受个体化营养导向远程照护患者的肝脏相关事件风险降低 Shaminie J. Athinarayanan, Adam J. Wolfberg, Priya V. Shanmugam, Bilal A. Hameed, Maurizio Bonacini Hepatology. September 2026: 84(3):870‑885 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 24 T‑ and B‑cell–targeting DNA/MVA HCV vaccines induce strong and broad cellular and humoral immunity in mice and rhesus macaques 靶向T、B细胞的DNA/MVA丙型肝炎疫苗在小鼠与恒河猴体内诱导强效广谱细胞及体液免疫 Sheikh Abdul Rahman, Sailaja Gangadhara, John Gridley, Uchurappa Mala, Elizabeth J. Elrod, Nathalie Bédard, Julie Bruneau, Naglaa H. Shoukry, Arash Grakoui, Rama Rao Amara Hepatology. September 2026: 84(3):886‑899 25 Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis 实体器官移植中戊型肝炎二十年：单中心回顾性分析 Nassim Kamar, Florence Abravanel, Olivier Marion, Chloé Couat, Laure Esposito, Anne Laure Hebral, Laurence Lavayssière, David Ribes, Pierre Guy, Sébastien Lhomme, Olivier Cointault, Stanislas Faguer, Julie Bellière, Amandine Darres, Joelle Guitard, Chloé Médrano, Arnaud Del Bello, Jacques Izopet Hepatology. September 2026: 84(3):900‑909 Reviews（综述） 26 Portal sinusoidal vascular diseases: Assessment and therapy 门窦血管性疾病：评估与治疗 Maria Mironova, Harish Gopalakrishna, Christopher Koh, David E. Kleiner, Theo Heller Hepatology. September 2026: 84(3):910‑931 27 Assessment of liver injury potential of investigational medicines in drug development 药物研发过程中候选药物肝损伤风险评估 Naga Chalasani, Paul H. Hayashi, Debra Luffer‑Atlas, Arie Regev, Paul B. Watkins Hepatology. September 2026: 84(3):932‑951 28 Advances in imaging—Elastography 影像学进展——弹性成像 Elton Dajti, Adrian T. Huber, Giovanna Ferraioli, Annalisa Berzigotti Hepatology. September 2026: 84(3):952‑975 29 Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications 肝星状细胞异质性：功能特征与治疗价值 Yana Geng, Robert F. Schwabe Hepatology. September 2026: 84(3):976‑989 Special Article（专题论著） 30 Integrative Hepatology: Enhancing overall health to manage liver disease 整合肝病学：通过改善整体健康管理肝脏疾病 Jennifer C. Lai, Elliot B. Tapper, Puneeta Tandon Hepatology. September 2026: 84(3):990‑998 Position Paper（立场文件） 31 AASLD‑EASL Delphi consensus statement on surrogate endpoints and real‑world evidence in primary biliary cholangitis AASLD‑EASL关于原发性胆汁性胆管炎替代终点与现实证据德尔菲共识声明 American Association for the Study of Liver Diseases,European Association for the Study of the Liver Hepatology. September 2026: 84(3):999‑1024 Correspondence（读者来信） 32 Letter to the Editor: Clarifying the relative contributions of collagen architecture and stiffness to antitumor immunity in GIONF‑Enhanced PD‑1 blockade for cholangiocarcinoma 致编辑的信：阐明胶原结构与硬度在GIONF增强PD‑1阻断治疗胆管癌中对抗肿瘤免疫的相对作用 Dandan Weng, Guancheng Huang, Yingying Liu Hepatology. September 2026: 84(3):E53‑E54 33 Letter to the Editor: Hepatocyte‑derived extracellular vesicles promote endothelial pyroptosis in chronic liver disease: Undefined role of miR‑153‑3p 致编辑的信：肝细胞来源胞外囊泡促进慢性肝病内皮细胞焦亡：miR‑153‑3p作用尚不明确 Xinyi Hu, Qi Zhang, Lulu Wan, Mengyang Liu Hepatology. September 2026: 84(3):E55‑E56 Errata（勘误） 34 Erratum: NK‑cell–elicited gasdermin‑D–dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV‑related acute‑on‑chronic liver failure 勘误：NK细胞诱导GSDMD依赖的肝细胞焦亡促进中性粒细胞胞外网状陷阱形成参与乙肝相关慢加急性肝衰竭 Qiang Zhao, Dong‑Ping Chen, Hua‑Di Chen, Ying‑Zhe Wang, Wei Shi, Yi‑Tong Lu, Yi‑Zheng Ren, Yuankai Wu, Yi‑Hua Pang, Hong Deng, Xiaoshun He, Dong‑Ming Kuang, Zhiyong Guo Hepatology. September 2026: 84(3):E57‑E59 35 Erratum: RNF128 aggravates metabolic dysfunction–associated steatotic liver disease progression via stabilization of SCD1 勘误：RNF128通过稳定SCD1加重代谢功能障碍相关脂肪性肝病进展 Lei Cao, Wei Yang, Chaofan Wang, Changhao Liu, Wenqian Qi, Ruiqing Ren, Jie Zhang, Shuting Yu, Qian Li, Liangyu Cai, Xinyu Zhang, Xiaohong Wang, Wenhai Sui, Meng Zhang, Cheng Zhang Hepatology. September 2026: 84(3):E60‑E60 Hepatology[Jour] AND 84[volume] AND 4[issue]  肝脏病学 84卷4期 https://journals.lww.com/hep/pages/currenttoc.aspx Reviews（综述） 1 Response evaluation to systemic therapy in HCC: Current challenges and future perspectives 肝细胞癌全身治疗的疗效评估：当前挑战与未来展望 Mario Matute-González, Maxime Ronot, Victoria Chernyak, Bruno Sangro, Jordi Rimola Hepatology. October 2026: 84(4):1025-1048 2 Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma 开创精准时代：肝细胞癌免疫治疗的发展历程 Friedrich Foerster, Lucas Wiesmann, Paula Bark, Peter Robert Galle Hepatology. October 2026: 84(4):1049-1077 3 Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma 二线治疗之外：晚期肝细胞癌全身治疗的序贯策略 Marta Fortuny, Landon L. Chan, Leonardo G. da Fonseca, Ghassan K. Abou-Alfa, Stephen L. Chan, María Reig Hepatology. October 2026: 84(4):1078-1095 4 Clinical utilization of testing for cell-free DNA in hepatocellular cancer 游离DNA检测在肝细胞癌中的临床应用 Jasmine J. Wang, Yi-Te Lee, Amy K. Kim, Augusto Villanueva, Amit G. Singal, Ju Dong Yang Hepatology. October 2026: 84(4):1096-1120 5 Incorporating artificial intelligence into imaging for surveillance and diagnosis of liver cancer: Innovations, challenges, and clinical translation 人工智能融入肝癌筛查与诊断影像：创新、挑战与临床转化 Maxime Ronot, Julien Calderaro Hepatology. October 2026: 84(4):1121-1132 6 Anatomic subsets of cholangiocarcinoma: More different than alike 胆管癌解剖亚型：共性有限，差异显著 Yawen Dong, Hannah E. Stumpf, Rory L. Smoot, Patrick P. Starlinger, Mark M. Yarchoan, Gregory J. Gores, Sumera I. Ilyas Hepatology. October 2026: 84(4):1133-1156 7 Evolving precision: Updates in targeted therapy for cholangiocarcinoma 精准治疗持续进展：胆管癌靶向治疗新进展 Giulia Tesini, Halima Ibrahim, Lorenza Rimassa, Chiara Braconi Hepatology. October 2026: 84(4):1157-1180 8 The rise of transplant oncology in primary liver cancer and metastatic disease 移植肿瘤学在原发性肝癌及转移性疾病中的兴起 Charles-Henri Wassmer, Maximiliano Gelli, Tiffany Cho Wong, Zhihao Li, Anudari Zorigtbaatar, Rebecca Marino, Laia Aceituno Sierra, René Adam, Albert Chi Chan, Julie Heimbach, Pål Dag Line, Vincenzo Mazzaferro, Gonzalo Sapisochin, Parissa Tabrizian, Arndt Vogel, Christian Toso Hepatology. October 2026: 84(4):1181-1208 9 Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma 纤维板层癌诊疗临床指南 Allison F. O’Neill, Emily L. Zeme, Ghassan K. Abou-Alfa, Marina Baretti, Alexander J. Bondoc, Alanna Church, Cristina R. Ferrone, Megan Fitzgerald, James I. Geller, Anne E. Gill, William P. Harris, Heung Bae Kim, Sunyoung S. Lee, Kevin X. Liu, Michael V. Ortiz, Arun Rangaswami, Kimberly J. Riehle, Abby R. Rosenberg, Michael S. Torbenson, Mark Yarchoan, John D. Gordan Hepatology. October 2026: 84(4):1209-1228 10 Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer 破解肿瘤图谱：肝细胞癌多组学与空间生物学研究启示 Dawiyat Massoudi, Ankit Srivastava, Renumathy Dhanasekaran Hepatology. October 2026: 84(4):1229-1245 Hepatology[Jour] AND 84[volume] AND 5[issue]  肝脏病学 84卷5期 https://journals.lww.com/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 A gentler squeeze: A first signal from OCE-205, a selective V1a mixed agonist–antagonist for hepatorenal syndrome–acute kidney injury 温和调控：选择性V1a混合激动-拮抗剂OCE-205用于肝肾综合征合并急性肾损伤的初步研究结果 Prowpanga Udompap Hepatology. November 2026: 84(5):1247-1248 2 Present but not prescient: Cardiometabolic risk factors in alcohol-associated hepatitis 存在但不具备预测价值：酒精相关性肝炎的心代谢危险因素 Enis H. Ozmert Hepatology. November 2026: 84(5):1249-1250 3 Turning down the ammonia dial: Phase 2a evidence for YAQ007 in cirrhosis 下调血氨水平：YAQ007用于肝硬化的2a期临床证据 Hanna Erickson Hepatology. November 2026: 84(5):1251-1252 4 Rethinking albumin after paracentesis: It’s not just about the volume 重新审视腹腔穿刺术后白蛋白应用：不只是容量问题 Kevin Houston, Juan Pablo Arab Hepatology. November 2026: 84(5):1253-1254 Editorials（社论） 5 Radiomics beyond the visible—Decoding tumor heterogeneity to guide combination therapy of intermediate-stage HCC 超越可视影像的放射组学——解析肿瘤异质性指导中期肝细胞癌联合治疗 William Lotter, Julius Chapiro Hepatology. November 2026: 84(5):1255-1257 6 Metabolic reprogramming in macrophages: A glutamine rescue in β-catenin mutant hepatocellular carcinoma 巨噬细胞代谢重编程：β-连环蛋白突变型肝细胞癌中的谷氨酰胺代偿机制 Gregory Kenneth Muliawan, Terence Kin Lee Hepatology. November 2026: 84(5):1258-1261 7 Unraveling the immunogenetic architecture of cholangiocarcinoma 解析胆管癌的免疫遗传结构 Claudia Wing-Kwan Wu, Rashid N. Lui Hepatology. November 2026: 84(5):1262-1263 8 Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence 合并大血管侵犯的肝细胞癌：梳理异质性研究证据 Manon Allaire, Irene Bargellini Hepatology. November 2026: 84(5):1264-1266 9 B-BEST: Profiling the intrahepatic HBV reservoir at single-cell resolution B-BEST研究：单细胞水平解析肝内乙肝病毒储存库特征 Armando Andres Roca Suarez, Barbara Testoni, Fabien Zoulim Hepatology. November 2026: 84(5):1267-1269 Original Articles: Immune-Mediated Diseases, DILI, and Biliary Tract Disease（论著：免疫介导性疾病、药物性肝损伤与胆道疾病） 10 Liver transcriptome sequencing contributes to the molecular diagnosis of genetic liver diseases 肝脏转录组测序助力遗传性肝病的分子诊断 Ye Cheng, Zhong-Die Li, Zhi-Hong Guan,et al. Hepatology. November 2026: 84(5):1270-1285 Original Articles: Liver Cancer（论著：肝脏肿瘤） 11 Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma 靶向固醇O-酰基转移酶1重编程脂肪酸代谢并揭示肝细胞癌的免疫脆弱点 Huanhuan Ma, Vanilla Xin Zhang, Yu Man Tsui, et al. Hepatology. November 2026: 84(5):1286-1302 12 Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204) 基于影像生物标志物解析肿瘤异质性预测肝细胞癌经动脉化疗栓塞联合免疫及靶向治疗疗效（CHANCE2204研究） Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, et al. Hepatology. November 2026: 84(5):1303-1316 13 Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming β-连环蛋白突变肝细胞癌中谷氨酰胺合成酶缺失通过巨噬细胞代谢重编程促进肿瘤负荷增加 Evan R. Delgado, Panari Patel, Junyan Tao, et al. Hepatology. November 2026: 84(5):1317-1334 14 Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses 通过全基因组关联研究及整合分析揭示胆管癌及其亚型的遗传图谱 Younghun Han, Jinyoung Byun, Caitlin J. VanLith, et al. Hepatology. November 2026: 84(5):1335-1351 15 Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole 第二代抗精神病药阿立哌唑用于肝细胞癌的化学预防 Nevena Slović, Sumit Mishra, Subhojit Paul, et al. Hepatology. November 2026: 84(5):1352-1370 16 Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria 合并大血管侵犯肝细胞癌：基于简易预后标准的初始局部治疗综述及生存Meta分析 Marta Fortuny, Antonio De Rosa, Ignacio Roca, et al. Hepatology. November 2026: 84(5):1371-1380 17 Hepatectomy alters adjuvant anti–PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy 肝切除术改变肝细胞癌小鼠模型中辅助抗PD-1的作用，但不影响新辅助治疗疗效 Roqiya Bouguerra, Sofia El Hajji, Charles-Henri Wassmer, et al. Hepatology. November 2026: 84(5):1381-1395 Original Articles: Liver Pathobiology（论著：肝脏病理生物学） 18 Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages 髓系细胞CD36缺失通过增强巨噬细胞适应性免疫减轻肝纤维化 Liangyun Li, Yilong Fang, Jintong Zhang, et al. Hepatology. November 2026: 84(5):1396-1414 Original Articles: Liver Failure/Cirrhosis/Portal Hypertension（论著：肝衰竭/肝硬化/门静脉高压） 19 Featured video: Complications of chronic liver disease 精选视频：慢性肝病并发症 Jacqueline G. O’Leary Hepatology. November 2026: 84(5):E61-E61 20 Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study 门诊腹腔穿刺术后静脉输注白蛋白降低急性肾损伤住院风险：一项全国队列研究 Nadim Mahmud, Max S. Schechter, Siqi Zhang, et al. Hepatology. November 2026: 84(5):1415-1425 21 OCE-205, a selective V1a receptor mixed agonist–antagonist, for the treatment of hepatorenal syndrome–acute kidney injury: A phase 2 randomized trial 选择性V1a受体混合激动-拮抗剂OCE-205治疗肝肾综合征合并急性肾损伤：一项2期随机试验 Andrew S. Allegretti, Giuseppe Cullaro, Paul Kwo, et al. Hepatology. November 2026: 84(5):1426-1436 22 A randomized, open-label, phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis 评估YAQ007与利福昔明用于肝硬化的安全性、药效学及药代动力学的随机开放2a期研究 Maria Pilar Ballester, Juan Antonio Carbonell-Asins, Ahmed Elshabrawi, et al. Hepatology. November 2026: 84(5):1437-1450 Original Articles: Steatohepatitis（论著：脂肪性肝炎） 23 Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction 年龄与性别影响他汀治疗的转录组应答，调控全身代谢异常状态下的肝脏衰老 David S. Umbaugh, Liuyang Wang, Kuo Du, et al. Hepatology. November 2026: 84(5):1451-1468 24 Hepatic GPR75 exacerbates MASH through GNAI2-dependent signaling 肝脏GPR75通过GNAI2依赖信号通路加重代谢相关脂肪性肝炎 Xule Yang, Na Yang, Zhihao Cheng, et al. Hepatology. November 2026: 84(5):1469-1485 25 Longitudinal assessment of the circulating cytokine profile of severe alcohol-associated hepatitis 重症酒精相关性肝炎循环细胞因子谱的纵向评估 David Tornai, Mack C. Mitchell, Craig J. McClain, et al. Hepatology. November 2026: 84(5):1486-1502 26 Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study 探讨代谢异常与酒精相关性肝炎的相互作用：一项全球性研究 Vania Cari, María I. Perez, Ignacio Tellez, et al. Hepatology. November 2026: 84(5):1503-1513 Original Articles: Viral Hepatitis（论著：病毒性肝炎） 27 A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B 甲磺酸普拉德福韦对比富马酸替诺福韦酯治疗中国慢性乙型肝炎患者的随机双盲3期非劣效试验 Yanhang Gao, Xinrui Wang, Zhongfeng Wang, et al. Hepatology. November 2026: 84(5):1514-1528 28 Host-viral interaction of HBV infection revealed by single-cell transcriptome jointly profiling the viral replication state 联合病毒复制状态的单细胞转录组分析揭示乙肝病毒感染的宿主-病毒相互作用 Yanfang Huang, Hongyuan Xue, Jinhang He, et al. Hepatology. November 2026: 84(5):1529-1547 Reviews（综述） 29 Detecting at-risk steatotic liver disease and liver fibrosis in the community 社区高危脂肪性肝病及肝纤维化筛查 Leon A. Adams, Maja Thiele, Emmanuel A. Tsochatzis Hepatology. November 2026: 84(5):1548-1566 30 Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease 细胞治疗与肝脏类器官构建技术：终末期肝病的潜力治疗策略 Shaoyang Qin, Xiaochen Bo, Hongyuan Liu, et al. Hepatology. November 2026: 84(5):1567-1586 Special Article（专题论著） 31 Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium 肝细胞癌风险分层模型的构建与验证：转化肝癌研究联盟提出的框架 Fasiha Kanwal, Ziding Feng, Yujin Hoshida, et al. Hepatology. November 2026: 84(5):1587-1604 Correspondence（通信） 32 Letter to the Editor: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC 致编辑信：手术时机影响肝细胞癌肝切除术后辅助PD-1治疗疗效 Yanyu Zhang, Yehao Zhang, Tingting Hu Hepatology. November 2026: 84(5):E62-E63 33 Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC 回复：手术时机影响肝细胞癌肝切除术后辅助PD-1治疗疗效 Roqiya Bouguerra, Sofia El Hajji, Charles Wassmer, et al. Hepatology. November 2026: 84(5):E64-E65 34 Letter to the Editor: Methodological considerations for ITH quantification and model integration 致编辑信：肿瘤内异质性定量及模型整合的方法学考量 Zhengtong Zhou, Hua Zhou Hepatology. November 2026: 84(5):E66-E67 35 Letter to the Editor: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC 致编辑信：对解析肝细胞癌肿瘤异质性增设临床评分的建议 Jixu Guo, Shuiping Yu Hepatology. November 2026: 84(5):E68-E68 36 Reply: The suggestion for additional clinical scores in decoding tumor heterogeneity in HCC 回复：对解析肝细胞癌肿瘤异质性增设临床评分的建议 Zhi-Cheng Jin, Gao-Jun Teng Hepatology. November 2026: 84(5):E69-E69 Errata（勘误） 37 Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study 勘误：代谢相关脂肪性肝病无创检测的全球效能——G-MASLD研究启示 Zobair M. Younossi, Leyla de Avila, Salvatore Petta, et al. Hepatology. November 2026: 84(5):E70-E71 38 Erratum: Pathogenic Ifit1+ neutrophils driven by IRF7 promote liver injury and represent a therapeutic target in acute liver failure 勘误：IRF7介导的致病性Ifit1阳性中性粒细胞加重肝损伤，是急性肝衰竭的治疗靶点 Yu Lu, Yi Zhang, Lina Sun, Fangyuan Gao, et al. Hepatology. November 2026: 84(5):E72-E72 39 Erratum: H19 promotes HCC bone metastasis through reducing osteoprotegerin expression in a protein phosphatase 1 catalytic subunit alpha/p38 mitogen-activated protein kinase-dependent manner and sponging microRNA 200b-3p 勘误：H19通过蛋白磷酸酶1催化亚基α/p38丝裂原活化蛋白激酶通路下调骨保护素并吸附微小RNA 200b-3p，促进肝细胞癌骨转移 Zhao Huang, Liang Chu, Junnan Liang, et al. Hepatology. November 2026: 84(5):E73-E74 40 Erratum: GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes 勘误：GLP-1受体激动剂联合SGLT-2抑制剂对合并2型糖尿病的代谢相关脂肪性肝病成人严重肝脏及心血管不良事件风险的影响 Xianhua Mao, Hong Fan, Man-Fung Yuen, et al. Hepatology. November 2026: 84(5):E75-E75 41 Erratum: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma 勘误：CD151与/或c-Met过表达在肝细胞癌预后预测中的价值 Ai-Wu Ke, Guo-Ming Shi, Jian Zhou, et al. Hepatology. November 2026: 84(5):E76-E78